<DOC>
	<DOCNO>NCT00887822</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety bevacizumab combination capecitabine cisplatin versus placebo combination capecitabine cisplatin participant receive prior chemotherapy advance metastatic gastric cancer . Participants randomize one two treatment group Bevacizumab + Capecitabine/Cisplatin ( experimental arm ) Placebo + Capecitabine/Cisplatin ( control arm ) .</brief_summary>
	<brief_title>A Study Bevacizumab ( Avastin ) Versus Placebo Combination With Capecitabine ( Xeloda ) Cisplatin First-Line Therapy Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically confirm adenocarcinoma stomach gastrooesophageal junction inoperable , locally advanced metastatic disease , amenable curative therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0,1 2 Measurable disease nonmeasurable evaluable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST ) Previous chemotherapy locally advance metastatic gastric cancer Previous platinum antiangiogenic therapy Radiotherapy within 28 day randomization Evidence Central Nervous System ( CNS ) metastasis baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>